Subsequently, based on the LassoCox regression analysis, we established a novel 4 PRG (CASP4, GSDMC, IL18 and NLRP2) signature to further evaluate the overall survival of PAAD patients. This evidence concerns the gene CASP4 and pancreatic adenocarcinoma.